Overview

Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor

Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
SHR1459 is a selective small molecule BTK inhibitor developed by Jiangsu Hengrui medicine Limited, by inhibiting the phosphorylation of BTK and down regulation of BCR signal transduction pathway, And then selectively inhibit the proliferation and migration of B cell tumor.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.